Liver cirrhosis and portal hypertension in cystic fibrosis. 2003

Ori Efrati, and Asher Barak, and Dalit Modan-Moses, and Arie Augarten, and Daphna Vilozni, and Daniel Katznelson, and Amir Szeinberg, and Jacob Yahav, and Yoram Bujanover
Paediatric Department, The Chaim Sheba Medical Centre, Tel Hashomer, Israel. oryefraty@hotmail.com

OBJECTIVE Liver disease is the second cause of death in cystic fibrosis. The most deleterious complication of liver disease is portal hypertension, which has an estimated prevalence of up to 8%. Portal hypertension may manifest itself by splenomegaly, hypersplenism, gastro-oesophageal bleeding and ascites. The aim of our study was to determine the prevalence, risk factors and invasive management of portal hypertension at our centre. METHODS One hundred and fifty patients with cystic fibrosis were followed up between 1975 and 2000 in the national cystic fibrosis centre in Israel. Forty patients (27%) had liver disease. All underwent clinical evaluation and laboratory and imaging studies. RESULTS Portal hypertension was diagnosed in 10 patients (7%), of whom eight were male. The mean age at diagnosis was 11 years (range, 4-17 years). All had severe mutations of the cystic fibrosis transmembrane conductance regulator gene (the CFTR gene), pancreatic insufficiency, meconium ileus or distal intestinal obstruction syndrome and variceal bleeding. Seven patients underwent sclerotherapy to control acute bleeding. Four underwent portosystemic shunting (functioning up to 37 years). Two patients with severe lung and liver disease underwent transjugular intrahepatic portosystemic shunting, which provided bleeding control, but both died while waiting for lung/liver transplantation. One patient underwent liver transplantation due to liver failure and still had good liver and lung function 10 years later. CONCLUSIONS Portal hypertension is more common among Israeli patients with cystic fibrosis. The unique genetic composition of our population may explain this phenomenon. Risk factors include male gender, pancreatic insufficiency, severe CFTR mutations, meconium ileus and meconium ileus equivalent. Sclerotherapy is the main option to control oesophageal variceal bleeding, while portosystemic shunts offer a prolonged alternative treatment for refractory bleeding. A transjugular intrahepatic portosystemic shunt and liver transplantation may also be effective, but further research is required in order to establish their role.

UI MeSH Term Description Entries
D006975 Hypertension, Portal Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN. Cruveilhier-Baumgarten Disease,Cruveilhier-Baumgarten Syndrome,Cruveilhier Baumgarten Disease,Cruveilhier Baumgarten Syndrome,Disease, Cruveilhier-Baumgarten,Portal Hypertension,Portal Hypertensions,Syndrome, Cruveilhier-Baumgarten
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011170 Portasystemic Shunt, Surgical Surgical venous shunt between the portal and systemic circulation to effect decompression of the portal circulation. It is performed primarily in the treatment of bleeding esophageal varices resulting from portal hypertension. Types of shunt include portacaval, splenorenal, mesocaval, splenocaval, left gastric-caval (coronary-caval), portarenal, umbilicorenal, and umbilicocaval. Portosystemic Shunt, Surgical,Portasystemic Shunt,Portosystemic Shunt,Shunt, Surgical Portasystemic,Shunt, Surgical Portosystemic,Surgical Portasystemic Shunt,Surgical Portosystemic Shunt,Portasystemic Shunts,Portasystemic Shunts, Surgical,Portosystemic Shunts,Portosystemic Shunts, Surgical,Shunt, Portasystemic,Shunt, Portosystemic,Shunts, Portasystemic,Shunts, Portosystemic,Shunts, Surgical Portasystemic,Shunts, Surgical Portosystemic,Surgical Portasystemic Shunts,Surgical Portosystemic Shunts
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D005260 Female Females

Related Publications

Ori Efrati, and Asher Barak, and Dalit Modan-Moses, and Arie Augarten, and Daphna Vilozni, and Daniel Katznelson, and Amir Szeinberg, and Jacob Yahav, and Yoram Bujanover
January 2013, Srpski arhiv za celokupno lekarstvo,
Ori Efrati, and Asher Barak, and Dalit Modan-Moses, and Arie Augarten, and Daphna Vilozni, and Daniel Katznelson, and Amir Szeinberg, and Jacob Yahav, and Yoram Bujanover
March 2011, Hepatology (Baltimore, Md.),
Ori Efrati, and Asher Barak, and Dalit Modan-Moses, and Arie Augarten, and Daphna Vilozni, and Daniel Katznelson, and Amir Szeinberg, and Jacob Yahav, and Yoram Bujanover
July 1999, Journal of hepatology,
Ori Efrati, and Asher Barak, and Dalit Modan-Moses, and Arie Augarten, and Daphna Vilozni, and Daniel Katznelson, and Amir Szeinberg, and Jacob Yahav, and Yoram Bujanover
May 1955, Bulletin of the New York Academy of Medicine,
Ori Efrati, and Asher Barak, and Dalit Modan-Moses, and Arie Augarten, and Daphna Vilozni, and Daniel Katznelson, and Amir Szeinberg, and Jacob Yahav, and Yoram Bujanover
September 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
Ori Efrati, and Asher Barak, and Dalit Modan-Moses, and Arie Augarten, and Daphna Vilozni, and Daniel Katznelson, and Amir Szeinberg, and Jacob Yahav, and Yoram Bujanover
April 1968, Journal of pediatric surgery,
Ori Efrati, and Asher Barak, and Dalit Modan-Moses, and Arie Augarten, and Daphna Vilozni, and Daniel Katznelson, and Amir Szeinberg, and Jacob Yahav, and Yoram Bujanover
January 1966, JAMA,
Ori Efrati, and Asher Barak, and Dalit Modan-Moses, and Arie Augarten, and Daphna Vilozni, and Daniel Katznelson, and Amir Szeinberg, and Jacob Yahav, and Yoram Bujanover
May 1960, Maanedsskrift for praktisk laegegerning og social Medicin,
Ori Efrati, and Asher Barak, and Dalit Modan-Moses, and Arie Augarten, and Daphna Vilozni, and Daniel Katznelson, and Amir Szeinberg, and Jacob Yahav, and Yoram Bujanover
December 1966, Vestnik khirurgii imeni I. I. Grekova,
Ori Efrati, and Asher Barak, and Dalit Modan-Moses, and Arie Augarten, and Daphna Vilozni, and Daniel Katznelson, and Amir Szeinberg, and Jacob Yahav, and Yoram Bujanover
September 1993, Archives of disease in childhood,
Copied contents to your clipboard!